glp 1 agonists addiction GLP-1 Anti-Obesity Rx and Alcohol and Substance Use Disorders Frontiers | The therapeutic potential
Description
Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.
Retatrutide vs Semaglutide: Evidence-based comparison of the investigational triple GIP/GLP-1/glucagon agonist versus the FDA-approved GLP-1 agonist
The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031
However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors
95% CI 0.97, 1.15)
10.91.0 Eq/min/gkw)
